Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
High-sensitivity cardiac troponin (hs-cTn) assays facilitate the ruling-out of myocardial infarction (MI) but identify a high number of patients with elevated troponin levels but without MI. Consequently, the term myocardial injury was included in the latest universal definition of MI. In the High-STEACS trial, use of a hs-cTnI assay was safe but had no prognostic benefit.
Cardiovascular disease and cancer share several risk factors. Patients with heart failure have a higher rate of cancer than healthy control populations. Meijers and colleagues have taken this association a step further to present new evidence suggesting that, beyond simply sharing root causes, heart failure might actually cause cancer.
A wealth of data that culminated in a large clinical trial established that IL-1β blockade has beneficial effects in atherosclerotic cardiovascular disease. A new study in gene-targeted mice challenges this view by showing atheroprotective effects of IL-1β.
The KardiaBand, which records a rhythm strip from an AppleWatch, was paired with an app for automated detection of atrial fibrillation. A new study by Bumgarner and colleagues is one of the first studies to examine the feasibility of using a smartwatch to discriminate between sinus rhythm and atrial fibrillation.
Early studies showing that KIT+ cardiac progenitor cells (CPCs) could differentiate into cardiomyocytes generated excitement regarding their potential therapeutic application. Subsequent studies called their functional relevance into question, and while claims for a contribution of KIT+ CPCs to myocardial regeneration continue, two new studies confirm the doubts about their relevance to cardiomyogenesis and provide unexpected new insights.
The immaturity of stem cell-derived cardiomyocytes has impeded their use for in vitro disease modelling, cardiotoxicity assays, and cell-replacement therapy. Ronaldson-Bouchard and colleagues report unparalleled in vitro maturation of stem cell-derived cardiomyocytes. This advance promises to unlock the translational potential of these cells.
Hyperlipidaemia is an important risk factor for coronary artery disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in Angptl3, encoding a lipoprotein lipase inhibitor. Treatment was effective in both wild-type and Ldlr−/− mice and had a similar effect to that of Pcsk9-targeted genome editing, without causing off-target mutations.
Advances in breast cancer therapy mean that more women are surviving cancer but are at increased risk of cardiovascular disease (CVD). In a statement released by the AHA, Mehta and colleagues summarize the intersection between breast cancer and CVD, and highlight the importance of vigilance in preventive measures.
Catheter ablation for atrial fibrillation (AF) in patients with concomitant AF and heart failure (HF) is associated with significantly lower HF hospitalizations and all-cause mortality compared with medical therapy, according to the CASTLE-AF trial. This trial, along with previous trials such as AATAC, highlights the important role of AF ablation in the management of patients with HF and AF.
The radical new US hypertension guidelines, released 3 years after the previous scientific statement, have implications far beyond their intended recipients. They include a new definition for hypertension, lower treatment targets, and extended guidance on the implementation of multidisciplinary care, including self-monitoring of blood pressure. Some recommendations are likely to generate controversy.
